The FDA has granted pre-market approval (PMA) for the use of Abiomed's (Danvers, Massachusetts) Impella 2.5 heart pump during elective and urgent high risk percutaneous coronary intervention (PCI) procedures. Abiomed said the approval is based on clinical data the company submitted to the FDA to support this PMA as part of the 515 initiative. Read More
